These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 37731835)
41. Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: Yousef RG; Elwan A; Gobaara IMM; Mehany ABM; Eldehna WM; El-Metwally SA; A Alsfouk B; Elkaeed EB; Metwaly AM; Eissa IH J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2206-2222. PubMed ID: 35980113 [TBL] [Abstract][Full Text] [Related]
42. Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity. Mahmoud HK; Farghaly TA; Abdulwahab HG; Al-Qurashi NT; Shaaban MR Eur J Med Chem; 2020 Dec; 208():112752. PubMed ID: 32947227 [TBL] [Abstract][Full Text] [Related]
43. A new class of anti-proliferative activity and apoptotic inducer with molecular docking studies for a novel of 1,3-dithiolo[4,5- Ismail MA; Abusaif MS; El-Gaby MSA; Ammar YA; Ragab A RSC Adv; 2023 Apr; 13(18):12589-12608. PubMed ID: 37101951 [TBL] [Abstract][Full Text] [Related]
44. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586 [TBL] [Abstract][Full Text] [Related]
49. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors. Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416 [TBL] [Abstract][Full Text] [Related]
50. Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Mahdy HA; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; El-Gamal KMA; El-Sharkawy A; Elhendawy MA; Radwan MM; Elsohly MA; Eissa IH Bioorg Chem; 2020 Jan; 94():103422. PubMed ID: 31812261 [TBL] [Abstract][Full Text] [Related]
51. Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR-2 inhibition, and down-regulation of PI3K/AKT/mTOR signaling pathway. Seif SE; Mahmoud Z; Wardakhan WW; Abdou AM; Hassan RA Drug Dev Res; 2023 Aug; 84(5):839-860. PubMed ID: 37016480 [TBL] [Abstract][Full Text] [Related]
52. Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and Al-Muntaser SM; Al-Karmalawy AA; El-Naggar AM; Ali AK; Abd El-Sattar NEA; Abbass EM RSC Adv; 2023 Apr; 13(18):12184-12203. PubMed ID: 37082377 [TBL] [Abstract][Full Text] [Related]
53. Design, synthesis and molecular modeling of new quinazolin-4(3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation. Abdallah AE; Eissa SI; Al Ward MMS; Mabrouk RR; Mehany ABM; El-Zahabi MA Bioorg Chem; 2021 Apr; 109():104695. PubMed ID: 33647743 [TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors. Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467 [TBL] [Abstract][Full Text] [Related]
55. New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies. Elkaeed EB; Taghour MS; Mahdy HA; Eldehna WM; El-Deeb NM; Kenawy AM; A Alsfouk B; Dahab MA; Metwaly AM; Eissa IH; El-Zahabi MA J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2191-2205. PubMed ID: 35975321 [TBL] [Abstract][Full Text] [Related]
56. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents. Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477 [TBL] [Abstract][Full Text] [Related]
57. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
58. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975 [TBL] [Abstract][Full Text] [Related]
59. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation. Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of the anti-proliferative activity of 2-oxo-pyridine and 1' Raslan RR; Ammar YA; Fouad SA; Hessein SA; Shmiess NAM; Ragab A RSC Adv; 2023 Mar; 13(15):10440-10458. PubMed ID: 37020892 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]